Literature DB >> 16870487

Botulinum toxin: clinical use.

Daniel D Truong1, Wolfgang H Jost.   

Abstract

Since its development for the use of blepharospasm and strabismus more than 2.5 decades ago, botulinum neurotoxin (BoNT) has become a versatile drug in various fields of medicine. It is the standard of care in different disorders such as cervical dystonia, hemifacial spasm, focal spasticity, hyperhidrosis, ophthalmological and otolaryngeal disorders. It has also found widespread use in cosmetic applications. Many other indications are currently under investigation, including gastroenterologic and urologic indications, analgesic management and migraine. This paper is an extensive review of the spectrum of BoNT clinical applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870487     DOI: 10.1016/j.parkreldis.2006.06.002

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  36 in total

1.  Synthesis and evaluation of library of betulin derivatives against the botulinum neurotoxin A protease.

Authors:  Peter Šilhár; Sami Alakurtti; Kateřina Čapková; Feng Xiaochuan; Charles B Shoemaker; Jari Yli-Kauhaluoma; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2011-03-04       Impact factor: 2.823

2.  An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.

Authors:  Lisa M Eubanks; Mark S Hixon; Wei Jin; Sukwon Hong; Colin M Clancy; William H Tepp; Michael R Baldwin; Carl J Malizio; Michael C Goodnough; Joseph T Barbieri; Eric A Johnson; Dale L Boger; Tobin J Dickerson; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-09       Impact factor: 11.205

Review 3.  [Botulinum toxin treatment in the head and neck region: current aspects, developments, and problems].

Authors:  R Laskawi
Journal:  HNO       Date:  2007-06       Impact factor: 1.284

Review 4.  Evidence for the effectiveness of botulinum toxin for sialorrhoea.

Authors:  D D Truong; R Bhidayasiri
Journal:  J Neural Transm (Vienna)       Date:  2008-02-04       Impact factor: 3.575

5.  Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study.

Authors:  K Wohlfarth; I Schwandt; F Wegner; T Jürgens; G Gelbrich; A Wagner; U Bogdahn; W Schulte-Mattler
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

6.  Selection of Muscles for Botulinum Toxin Injections in Cervical Dystonia.

Authors:  Wolfgang H Jost; Laurent Tatu
Journal:  Mov Disord Clin Pract       Date:  2015-05-07

7.  Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with Blepharospasm.

Authors:  Francisco Vivancos-Matellano; Ana Rodríguez-Sanz; Yolanda Herrero-Infante; Javier Mascías-Cadavid
Journal:  Neuroophthalmology       Date:  2018-11-26

8.  Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain.

Authors:  Hajime Seki; Sabine Pellett; Peter Silhár; G Neil Stowe; Beatriz Blanco; Matthew A Lardy; Eric A Johnson; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2013-12-08       Impact factor: 3.641

9.  Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: synthesis, crystallography, modeling, kinetic and cellular based studies.

Authors:  Peter Šilhár; Nicholas R Silvaggi; Sabine Pellett; Kateřina Čapková; Eric A Johnson; Karen N Allen; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2012-12-20       Impact factor: 3.641

Review 10.  Botulinum toxin in the treatment of blepharospasm and hemifacial spasm.

Authors:  C Kenney; J Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2007-06-11       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.